CannabisNewsBreaks

FridayJan 19, 2024 2:04 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) CEO to Present at January Water Tower Research Fireside Chat

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, announced that CEO Eric A Adams will be participating in the upcoming Water Tower Research Fireside Chat Series. This month’s chat is scheduled to begin at 1 p.m. ET on Jan. 25, 2024. According to the announcement, topics discussed during the event will include an overview of InMed’s pharmaceutical pipeline in Alzheimer’s and ocular as well as a discussion about cannabinoids and their possible role in the treatment of Alzheimer’s. In addition, the chat will include a look at upcoming 2024…

Continue Reading

WednesdayJan 17, 2024 3:53 pm

CannabisNewsBreaks – Astrotech Corporation (NASDAQ: ASTC) Engages IBN for Corporate Communications Expertise

Astrotech (NASDAQ: ASTC) is an instrumentation company focused on commercializing its proprietary ATi Mass Spectrometer Technology(TM) that is now used in airports and agriculture applications around the world. The company today announced that it has selected IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its corporate communications initiatives. Astrotech continues to expand its ATi Mass Spectrometer Technology into new markets and recently launched its newest Pro-Control-1000(TM) product line of instrumentation designed to improve chemical manufacturing efficiencies. Astrotech also announced the formation of its newest wholly owned subsidiary, Pro-Control Inc., which has an…

Continue Reading

TuesdayJan 16, 2024 3:17 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Extensive GLP-1 Study Program

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today unveiled a comprehensive planned applied research program to thoroughly evaluate DehydraTECH for the improved delivery of GLP-1 drugs, designed to support prospective commercial partnering with global pharmaceutical companies. In a recent human pilot study with seven volunteers, Lexaria demonstrated superior pharmacokinetic (“PK”) oral delivery performance of the DehydraTECH-enhanced glucagon-like peptide-1 (“GLP-1”) drug semaglutide, available commercially in the branded product Rybelsus(R). The positive results were sufficient to encourage a much more thorough and expanded investigation. The objective of the new planned studies, as detailed in the announcement, is…

Continue Reading

TuesdayJan 16, 2024 2:40 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Business Update, Milestones

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today outlined key accomplishments from 2023 and provided key strategic priorities for 2024. “In 2023, we experienced significant progress in both InMed’s pharmaceutical drug development and in BayMedica’s health and wellness initiatives. Our primary accomplishments throughout the year included a number of key milestones, such as the completion of a phase 2 clinical trial and the launch of two new preclinical programs targeting the treatment of Alzheimer’s disease and age-related macular degeneration (‘AMD’),” said Eric A. Adams, InMed president and CEO.…

Continue Reading

FridayJan 12, 2024 1:30 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Grow Revenue and Commercial Opportunities Through Licensing

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is committed to providing healthier delivery methods of drugs and other active pharmaceutical ingredients (“APIs”) through its patented drug delivery technology, DehydraTECH(TM). “The company’s efforts have focused on several key segments, including hypertension, diabetes, antivirals, epilepsy, nicotine replacement, and more. This has been an ongoing process since 2016, with positive results achieved from various clinical studies thus far, showing up to 17x brain absorption improvements for oral administration of APIs… Human clinical studies have been conducted since 2018, with more on the way,” a recent article reads. “With…

Continue Reading

WednesdayJan 10, 2024 3:20 pm

CannabisNewsBreaks – Why Astrotech Corporation (NASDAQ: ASTC) Is ‘One to Watch’

Astrotech (NASDAQ: ASTC ) is an instrumentation company that designs, manufactures and commercializes solutions. These include mass spectrometry, process controls, chemical detectors and medical disease detection. The company is headquartered in Austin, Texas, and owns four subsidiaries: Astrotech Technologies Inc., 1st Detect Corp., AgLAB Inc., and BreathTech Corp. “Between 2016 and 2019, the company secured U.S. patents for its technology and achieved European Union (‘ECAC’) certification for the TRACER 1000(TM), the world’s first mass-spec Explosives Trace Detector (‘ETD’) used in airports worldwide,” a recent article reads. “Astrotech continues to innovate and add to its suite of products, including AgLAB-1000, a…

Continue Reading

TuesdayJan 09, 2024 1:19 pm

CannabisNewsBreaks – Branded Legacy Inc. (BLEG) Acquires All In Extracts LLC

Branded Legacy (OTC: BLEG), (soon to be known as Royal Enterprises Inc.), a burgeoning company in the pharmaceutical biotechnology sector, today announced its strategic acquisition of All In Extracts, a pioneering entity focused on medicinal ethnobotany. The milestone deal amplifies Branded Legacy’s focus on innovation, expansion and collaborative growth within the biotech community. “As soon as I met with the All In team, I knew something great was in the making,” said Branded Legacy CEO David Oswald. “It is a rare enough thing to find a company motivated primarily by the positive impact they can make on society. We are…

Continue Reading

TuesdayJan 09, 2024 12:14 pm

CannabisNewsBreaks – Software Effective Solutions Corp. (SFWJ) Featured in Bell2Bell Podcast

Software Effective Solutions (OTC: SFWJ) (d/b/a MedCana), a global infrastructure and holding company in the cannabis industry, was featured in the latest episode of the Bell2Bell Podcast, a part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Jose Gabriel Diaz, CEO of Software Effective Solutions, joined the program to provide an introduction to MedCana and its business model. “We are a U.S.-based holding company focused on developing infrastructure and cannabis companies around the world. Right now, the focus is primarily on markets outside of the U.S. that have already fully legalized pharmaceutical (and possibly some…

Continue Reading

FridayJan 05, 2024 1:20 pm

CannabisNewsBreaks – IBN, CannabisNewsWire Re-Engaged for NECANN’s 2024 Event Lineup

IBN, a multifaceted financial news and publishing company, today announced its expanded collaboration with NECANN, which specializes in orchestrating conventions that focus on the development and expansion of cannabis markets. Under the agreement, IBN’s CannabisNewsWire will continue to serve as the official newswire for the organization’s annual conference lineup. As part of the collaboration, IBN will amplify its support through its syndication network, providing comprehensive coverage for NECANN events. In collaboration with its network of 60+ online brands such as CannabisNewsWire and CannabisNewsWatch, IBN will deploy an extensive range of corporate-communications solutions to enhance visibility and recognition of conference participants…

Continue Reading

ThursdayJan 04, 2024 2:25 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Improve Oral Performance of Rybelsus(R)-Branded GLP-1 Drug Semaglutide

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced positive final results from its recently completed human Pilot Study #1 evaluating DehydraTECH(TM) technology for the oral delivery of the glucagon-like peptide-1 (“GLP-1”) drug semaglutide available commercially in the branded product Rybelsus(R). According to the announcement, the study was performed by a prominent university research center comparing a single 7 mg semaglutide dose of a Rybelsus tablet (“control”) to a matching dose from Rybelsus that had been compound formulated in capsule form using DehydraTECH processing technology enhancements (“DehydraTECH GLP-1”). In general, the DehydraTECH processing enabled improvements…

Continue Reading